BM
Therapeutic Areas
Neurotech Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ENCELTO™ (revakinagene taroretcel-lwey) / NT-501 | Idiopathic Macular Telangiectasia Type 2 (MacTel) | Approved |
Leadership Team at Neurotech Pharmaceuticals
RS
Richard Small
Chief Executive Officer
AG
Alex Gorsky
Lead Director, Board of Directors
RK
Rob Kissling, MD
Leadership Team (inferred)